TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6380897
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg suppositories)
Study: 30864768
Drug: ECA-Q (Embodied
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECA-Q (Embodied Conversational Agent for smoking cessation), 14-day program delivered through Tablet computers
Study: 25345257
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone cream (HC)
Study: 20356485
Drug: PCM group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCM group (pantoprazole 40 mg twice a day, clarithromycin 500 mg twice a day, metronidazole 400 mg twice a day for 7 days)
Study: 7841054
Drug: rIFN‐alpha 2c
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN‐alpha 2c monotherapy (30 micrograms m‐2 s.c. twice weekly)
Study: 7841054
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rIFN‐alpha 2c and rIFN‐gamma (30 micrograms m‐2 rIFN‐alpha 2c and 100 micrograms m‐2 rIFN‐gamma)
Study: 2221590
Drug: Budesonide, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 400 micrograms daily for 1 yr
Study: 515535
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg of Ba 253 as metered aerosols
Study: 515535
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of Ba 253 as metered aerosols
Study: 28082335
Drug: Theophylline (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (3.75 mg/Kg)
Study: 25474535
Drug: Acetaminophen 1
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 g every 6 hours for 3 days
Study: 24499497
Drug: NRL001 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 (5, 7.5 or 10 mg)
Study: 21577364
Drug: Lamotrigine (500.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (500.0 mg/d)
Study: 21577364
Drug: Topiramate (300.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (300.0 mg/d)
Study: 15610836
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg/kg/hr
Study: 15610836
Drug: Midazolam 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.6 mg/kg/hr
Study: 15610836
Drug: Midazolam 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.9 mg/kg/hr
Study: 15610836
Drug: Midazolam 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1.2 mg/kg/hr
Study: 10746845
Drug: Estradiol vaginal
Normalized name: Estradiol Vaginal
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol vaginal tablets (EVT)
Study: 3092610
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glyceryl trinitrate (GTN) transdermal patches for 6 hours during exercise
Study: 3092610
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glyceryl trinitrate (GTN) transdermal patches for 6 hours during sauna
Study: 23613481
Drug: Treatment‐As‐Usual (TAU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment‐As‐Usual (TAU)
Study: 21216318
Drug: Mandatory seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory seasonal influenza vaccine program
Study: 18305062
Drug: alemtuzumab, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: alemtuzumab, 30 mg i.v. over 2 hours three times per week on alternate days for a maximum of 12 weeks
Study: 18305062
Drug: chlorambucil, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorambucil, 40 mg/m(2) orally every 28 days for a maximum of 12 months
Study: 12547477
Drug: Mirtazapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (up to 45 mg/day)
Study: 10711525
Drug: Generic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic warfarin sodium product (Barr Laboratories)
Study: 8992905
Drug: Oral intubation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intubation, suxamethonium (1.5 mg/kg)
Study: 8992905
Drug: Oral intubation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intubation, vecuronium (0.1 mg/kg)
Study: 8992905
Drug: Nasal intubation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal intubation, suxamethonium (1.5 mg/kg)
Study: 8992905
Drug: Nasal intubation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal intubation, vecuronium (0.1 mg/kg)
Study: 26339899
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) with psychosocial support
Study: 25168524
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation of the posterior tibialis nerve (treatment group, n = 12)
Study: 17083352
Drug: 40 micro
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micro g ciclesonide
Study: 17083352
Drug: 80 micro
Normalized name: Folic acid 80 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 micro g ciclesonide
Study: 10999558
Drug: Ganaxolone (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaxolone (1500 mg/d on day 1 and 1875 mg/d on days 2 to 8, administered three times per day)
Study: 7938556
Drug: Selective MAOI-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective MAOI-A inhibitors (moclobemide, brofaromine)
Study: 3130175
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy (TAM 20 mg/day orally for 2 years in postmenopausal patients; oophorectomy before TAM in premenopausal patients)
Study: 3130175
Drug: Chemotherapy (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (0.06 mg/kg of mitomycin C IV and 100 mg cyclophosphamide orally for 6 months repeated four times in 2 years)
Study: 3130175
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (TAM with MMC + CPA chemotherapy)
Study: 3130175
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (TAM)
Study: 9694611
Drug: Chemotherapy (MMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (MMC + CPA)
Study: 3130175
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (MMC + CPA + TAM)
Study: 26819359
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (n = 11; total cumulative dose of 180 mg)
Study: 23339047
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (hyperinsulinaemic normoglycaemic clamp protocol)
Study: 23339047
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard therapy with no additional dietary supplement)
Study: 17277349
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (atorvastatin 80 mg/day, simvastatin 80 mg/day, or rosuvastatin 20-40 mg/day)
Study: 14560320
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC (0, 10 mg) administered five times/day during marijuana abstinence (days 9-14)
Study: 14560320
Drug: Divalproex (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex (0, 1500 mg/day) maintained for 29 days
Study: 11296186
Drug: Intermittent dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dobutamine infusion (IDI), 10 micromin, as needed (mean, once every 16 days, lasting for 12 to 48 h)
Study: 11296186
Drug: Oral amiodarone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone, 400 mg/d, and IDI, 10 microg/kg/min, for 8 h every 7 days
Study: 31514564
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy combined with power and strength exercises
Study: 24330810
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for chronic dizziness
Study: 24330810
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment for chronic dizziness
Study: 21670727
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol + dydrogesteron (37.5 µg/24h)
Study: 21670727
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol + medroxyprogesteron (50 µg/24h)
Study: 21670727
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol + noretisteron (1mg)
Study: 19424460
Drug: Health extension
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health extension workers (HEWs) trained to identify TB suspects, collect sputum, and provide directly observed treatment in intervention kebeles.
Study: 16771791
Drug: Bicalutamide 300
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 300 mg
Study: 16771791
Drug: Bicalutamide 450
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 450 mg
Study: 16771791
Drug: Bicalutamide 600
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 600 mg
Study: 15024300
Drug: Rosuvastatin (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (5, 10, 20, 40, or 80 mg)
Study: 15024300
Drug: Rosuvastatin (5-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (5-80 mg)
Study: 15024300
Drug: Rosuvastatin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (doses > 5 mg)
Study: 11122839
Drug: Short-course chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course chemotherapy regimens with radiotherapy
Study: 11122839
Drug: Short-course chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course chemotherapy regimens without radiotherapy
Study: 9262937
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication clinic approach
Study: 7967433
Drug: COALL therapy-protocol
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COALL therapy-protocol
Study: 16431378
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg tablets (fasted state)
Study: 16431378
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg tablets (fed state)
Study: 16431378
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg tablets
Study: 12860856
Drug: Pyridostigmine 30
Normalized name: Pyridostigmine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 30 mg
Study: 8872133
Drug: Cholesterol-lowering drug
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering drug (simvastatin)
Study: 8872133
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with TC > 249 mg/dl
Study: 6638413
Drug: Rush treatment
Normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rush treatment schedule
Study: 6638413
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment schedule
Study: 6638413
Drug: HBV treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV treatment
Study: 6638413
Drug: YJV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: YJV treatment
Study: 24886683
Drug: Interpersonal problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal problem-solving therapy plus treatment-as-usual
Study: 24886683
Drug: Treatment-as-usual alone
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual alone
Study: 22784777
Drug: Tanezumab (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab (2.5, 5, or 10 mg)
Study: 18855928
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 16-item identification test and detection threshold task
Study: 11409308
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (ventriculoscopic operation)
Study: 7935654
Drug: Zidovudine regimen
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine regimen (100 mg orally five times daily antepartum, 2 mg/kg intravenously during labor, 1 mg/kg/hour until delivery, and 2 mg/kg orally every six hours for six weeks for newborns)
Study: 3067924
Drug: Flurbiprofen 300
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 300 mg per day
Study: 3067924
Drug: Flurbiprofen b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen b.i.d. (twice daily)
Study: 3067924
Drug: Flurbiprofen t.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen t.i.d. (thrice daily)
Study: 22500659
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy exercises (control group)
Study: 18269639
Drug: Metformin (M
Normalized name: Product containing metformin (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (M group)
Study: 18269639
Drug: Glyburide (G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (G group)
Study: 12942563
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg as a 15-minute infusion)
Study: 10632128
Drug: G-suit inflation
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-suit inflation with LBNP (50 mm Hg)
Study: 10632128
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline without G-suit and LBNP)
Study: 8867251
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Ro 15‐8081 (divided into 2 doses)
Study: 8867251
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg/day, piroxicam in the morning and placebo in the evening)
Study: 28832393
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg body mass)
Study: 27605955
Drug: Prophylactic phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic phenylephrine weight adjusted dose infusion at 0.5 micrograms per kilogram per minute
Study: 27605955
Drug: Prophylactic phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic phenylephrine fixed dose infusion at 37.5 micrograms per minute
Study: 17414226
Drug: Duloxetine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 200 mg twice daily
Study: 10759934
Drug: Pericranial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericranial injection of 10 x 20 mouse units botulinum toxin A
Study: 1993808
Drug: Budesonide (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (reduced dose)
Study: 1993808
Drug: Budesonide (maintained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (maintained dose)
Study: 29359339
Drug: Subcrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal implants (adapted to soft tissue thickness)
Study: 29359339
Drug: Equicrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equicrestal implants (control)
Study: 28893309
Drug: Controlled-release oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release oxycodone/naloxone (OXN-CR)
Study: 28893309
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (OX-CR)
Study: 25339501
Drug: Intradiscal biacuplasty
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal biacuplasty (IDB) treatment
Study: 25339501
Drug: Cross-over from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross-over from sham to IDB treatment
Study: 18208600
Drug: Active test
Normalized name: Accu-Chek Active Test Strip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active test product (Hyal-Joint) 80 mg/day
Study: 1580284
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg once daily
Study: 1580284
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg once daily
Study: 30920122
Drug: Sorafenib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 600 mg/day
Study: 30920122
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg/day
Study: 30920122
Drug: Simulated dose-reduction
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated dose-reduction strategy of Sorafenib 800 mg/day for initial two cycles followed by dose reductions
Study: 29340321
Drug: Abatacept (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (modified CTLA4‐Ig) administered for 4 months
Study: 24127838
Drug: Penile vibratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile vibratory stimulation (PVS) device (FERTI CARE(®) vibrator), used daily for at least 1 week before surgery and for 6 weeks after catheter removal.
Study: 20202536
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g oral acetaminophen
Study: 9796070
Drug: Ultra-high dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-high dosage streptokinase (1.5 million U/h for 6h daily, n = 77)
Study: 9796070
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage streptokinase (100,000 U/h, n = 79)
Study: 9796070
Drug: Ultra-high dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-high dosage streptokinase (group A)
Study: 9796070
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage streptokinase (group B)
Study: 8582783
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate 200 mg orally for 30 days
Study: 17427
Drug: Fazadinium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium 0.5 mg/kg
Study: 29070055
Drug: Open excision
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open excision after arthroscopic treatment (Group B)
Study: 19632965
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CIMT) for 6 hours a day during waking hours for 4 weeks
Study: 19632965
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy only (Control)
Study: 17489733
Drug: Molecular markers
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular markers (e.g., ERCC1)
Study: 12201933
Drug: alpha-1 adrenoceptor
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-1 adrenoceptor antagonists (alpha-1ARA)
Study: 9659537
Drug: Theophylline (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (oral dose titrated twice daily)
Study: 25159300
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of teneligliptin every day (Group A)
Study: 25159300
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of teneligliptin every other day (Group B)
Study: 23017585
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum (CECT 7527, CECT 7528 and CECT 7529) - 1 capsule daily containing 1·2 × 10(9) colony-forming units for 12 weeks
Study: 23017585
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum (CECT 7527, CECT 7528 and CECT 7529) - 1 capsule daily for 12 weeks
Study: 19500037
Drug: Higher levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher levels of opsonizing antibodies to CS2 IEs
Study: 16371604
Drug: iv iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv iron alone (200 mg of iron sucrose on POD 1, 2, and 3)
Study: 16371604
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of iv iron and EPO (600 U x kg(‐1) on POD 1 and 3)
Study: 7753750
Drug: Long-term medical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term medical therapy
Study: 2225558
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion at 15 ml/hour using 10% CaCl2
Study: 2225558
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion at 20 ml/hour using 10% CaCl2
Study: 2225558
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion at 10 ml/hour using 10% CaCl2
Study: 2225558
Drug: Dialyzate with
Normalized name: Dialyvite 800 with Zinc Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialyzate with 1.5 mmol/l calcium
Study: 2225558
Drug: Dialyzate with
Normalized name: Dialyvite 800 with Zinc Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialyzate with 1.75 mmol/l calcium
Study: 2225558
Drug: Dialyzate calcium-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialyzate calcium-free with varying calcium infusion rates
Study: 487912
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g per day for 4 weeks)
Study: 487912
Drug: Antacid (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (210 ml/day for 4 weeks)